Alexander Redmond

Currently, I am completing the final year of my DPhil in the Rehwinkel lab, focusing on the characterisation of IFNAR2a, the soluble, secreted isoform of the type I interferon receptor. My research investigates IFNAR2a as a negative regulator of antiviral gene expression, functioning as a potential immune checkpoint modulator. By dissecting the molecular mechanisms of IFNAR2a-mediated immune regulation, I aim to illuminate new therapeutic strategies for viral diseases, autoimmunity, and cancer immunotherapy.

Academic & Industry Background

• DPhil (PhD) in Medical Science (Immunology), University of Oxford
  MRC WIMM Prize Studentship recipient, focused on type I interferon signaling.

• MRes Experimental & Translational Immunology, University College London
  Project on Treg modulation by HCMV.

• BSc Biomedical Sciences, University of Manchester
  Year in industry (Boehringer Ingelheim, Germany): utilised MALDI-TOF MS platform for high-throughput label-free enzyme inhibitor screening.

Innate Immunity, Cytokine Signaling, and Molecular Virology

My expertise is grounded in immunology, molecular biology, and virology, with extensive experience in:

• Genetic manipulation of in vivo models (including generating and phenotyping IFNAR2a knockouts)

• Flow cytometry, high-dimensional immunophenotyping and analysis of immune response

• Molecular & Protein Analysis - Quantitative PCR (qPCR) and transcriptomic analysis, Western blotting, ELISA

• Viral infection models (EMCV, HSV-1, human cytomegalovirus)

• Assay development and high-throughput screening approaches